Spectrum Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Spectrum Pharmaceuticals han disminuido a una tasa media anual de -0.5%, mientras que en la industria Biotechs los beneficios crecieron en un 19.1% anualmente. Los ingresos han ido disminuyendo a una tasa media de 69.6% al año.

Información clave

-0.5%

Tasa de crecimiento de los beneficios

10.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-69.6%
Rentabilidad financiera	-252.6%
Margen neto	-263.2%
Última actualización de beneficios	31 Mar 2023

Actualizaciones de resultados anteriores recientes

No hay actualizaciones

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

Desglose de ingresos y gastos

Cómo gana y gasta dinero Spectrum Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:SPPI Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 23	26	-68	43	43
31 Dec 22	10	-78	39	42
30 Sep 22	0	-106	42	51
30 Jun 22	0	-117	45	59
31 Mar 22	0	-138	56	72
31 Dec 21	0	-158	60	87
30 Sep 21	0	-169	57	88
30 Jun 21	0	-184	60	92
31 Mar 21	0	-166	60	85
31 Dec 20	0	-171	60	81
30 Sep 20	0	-162	60	85
30 Jun 20	0	-140	58	78
31 Mar 20	0	-136	60	74
31 Dec 19	0	-135	60	79
30 Sep 19	0	-148	61	86
30 Jun 19	0	-191	61	84
31 Mar 19	0	-147	60	83
31 Dec 18	0	-127	63	75
30 Sep 18	29	-102	68	67
30 Jun 18	65	-51	74	66
31 Mar 18	99	-87	75	64
31 Dec 17	0	-101	65	52
30 Sep 17	135	-81	72	63
30 Jun 17	132	-81	73	59
31 Mar 17	132	-84	83	58
31 Dec 16	146	-70	86	59
30 Sep 16	162	-55	92	56
30 Jun 16	157	-56	92	55
31 Mar 16	168	-35	87	50
31 Dec 15	163	-53	88	51
30 Sep 15	164	-50	90	50
30 Jun 15	183	-42	94	54
31 Mar 15	185	-44	97	74
31 Dec 14	187	-46	97	70
30 Sep 14	176	-82	98	66
30 Jun 14	171	-78	99	65
31 Mar 14	157	-84	95	46
31 Dec 13	156	-62	94	47
30 Sep 13	184	-15	86	50
30 Jun 13	211	14	84	46
31 Mar 13	247	42	86	45
31 Dec 12	268	94	83	42
30 Sep 12	251	95	90	34

Ingresos de calidad: SPPI actualmente no es rentable.

Margen de beneficios creciente: SPPI actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: SPPI no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 0.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SPPI en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: SPPI no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).

Rentabilidad financiera

Alta ROE: SPPI tiene una rentabilidad financiera negativa (-252.59%), ya que actualmente no es rentable.

Spectrum Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Recent updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Price target decreased by 33% to US$1.26

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.17 loss

Price target decreased by 15% to US$2.65

Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

President notifies of intention to sell stock

Consensus revenue estimates increase by 161%

Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022

Spectrum Pharmaceuticals Announces Executive Changes

Forecast to breakeven in 2025

Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc

Spectrum Pharmaceuticals’ ROLVEDON™ Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Consensus revenue estimates increase by 16%

Spectrum Pharmaceuticals, Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Price target decreased to US$3.10

Price target decreased to US$4.13

Spectrum Pharmaceuticals Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Spectrum Pharmaceuticals Announces Commercial Availability of Rolvedon™ (Eflapegrastim-Xnst) Injection

No longer forecast to breakeven

Spectrum Pharmaceuticals, Inc. Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Price target decreased to US$5.40

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Consensus forecasts updated

Spectrum Pharmaceuticals Receives Food and Drug Administration Approval for ROLVEDON (eflapegrastim-xnst) Injection

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Consensus revenue estimates fall by 61%

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Consensus forecasts updated

Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to its Board of Directors

Price target decreased to US$5.60

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Price target decreased to US$5.60

Spectrum Pharmaceuticals: Some Last Words

Spectrum Pharmaceuticals, Inc. Announces Resignation of Kurt Gustafson as Chief Financial Officer

Spectrum Pharmaceuticals, Inc. Announces Acceptance of New Drug Application Filing for Poziotinib

Spectrum Pharmaceuticals Announces Strategic Restructuring

Forecast to breakeven in 2024

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals, Inc. Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at European Society for Medical Oncology Congress 2021

Pomerantz LLP Announces the Filing of Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers

Consensus revenue estimates fall to US$2.30m

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

No longer forecast to breakeven

Price target decreased to US$9.40

High number of new directors

Spectrum's Big Approval: Any Day Now

Spectrum Pharmaceuticals, Inc.(NasdaqGS:SPPI) dropped from Russell 3000E Value Index

Consensus revenue estimates fall to US$20.0m

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the Zenith20 Clinical Trial

Spectrum Pharmaceuticals Announces Initiation of Pre-Approval Inspection for ROLONTIS®

FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Forecast breakeven pushed back to 2024

Consensus forecasts updated

FDA Grants Fast Track Designation to Spectrum Pharmaceuticals, Inc.'s Poziotinib

New 90-day low: US$3.28

Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib At the ESMO TAT Virtual Congress 2021

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Spectrum Pharmaceuticals Announces Two Oral Presentations at Upcoming IASLC 2020 World Conference on Lung Cancer

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like